A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average ...
Medscape4d
Could Gene Therapy for RA Soon Be Ready to ‘Take Off’?
Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...
Nanomachines loaded with wine ingredients overcome gene therapy challenges
Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...
pharmaphorum5d
Clinical trends for 2025: A year of change
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
TMCnet5d
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at The Macula Society's 48th Annual Meeting
Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...
Hansa Biopharma AB: Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced ...
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results. Søren ...
Appointment of Joint Corporate Broker and Joint Financial Adviser
OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies ...